Immunogenicity of Dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5091-5098

  Lesterhuis, W Joost ^a   De Vries, Ijolanda M ^a   Schreibelt, G ^a   Schuurhuis, Danita H ^a   Aarntzen, Erik H ^a   De Boer, Annemiek ^a   Scharenborg, Nicole M ^a   Van Rakt, Mandy D E ^a   Hesselink, Erik J ^b   Figdor, Carl G ^a   Adema, Gosse J ^a   Punt, Cornelis J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen loading; Ceapeptide; Colorectal cancer; Dendritic cells; Electroporation; Immunotherapy; MRNA; Vaccination

Indexed keywords

B LYMPHOCYTE ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN HLA A2 BINDING PEPTIDE LOADED; CARCINOEMBRYONIC ANTIGEN MESSENGER RNA; DENDRITIC CELL VACCINE; KEYHOLE LIMPET HEMOCYANIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CANCER IMMUNIZATION; CANCER PATIENT; CLINICAL ARTICLE; COLITIS; COLORECTAL CANCER; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DIARRHEA; DRUG FEVER; FLU LIKE SYNDROME; GENETIC TRANSFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; INJECTION SITE REACTION; LIVER METASTASIS; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SIDE EFFECT; SKIN TEST; TREATMENT OUTCOME;

CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HEMOCYANIN; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFECTION;

EID: 78751504910     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Steinman RM and Banchereau J: Taking dendritic cells into medicine. Nature 449: 419-426, 2007.
2. Lesterhuis WJ, Aarntzen EHJG, Vries UM, Schuurhuis DH, Figdor CG, Adema GJ, and Punt CJA: Dendritic cell vaccines in melanoma: From promise to proof? Crit Rev Oncol Hematol 66: 118-134, 2008.
3. Figdor CG, de Vries IJM, Lesterhuis WJ, and Melief CJM: Dendritic cell immunotherapy: mapping the way. Nat Med 10: 475-480, 2004.
4. Sullenger BA and Gilboa E: Emerging clinical applications of RNA. Nature 418: 252-258, 2002.
5. Van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR and Berneman ZN: Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 95: 49-56, 2001.
6. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E and Lyerly HK: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235: 540-549, 2002. (Pubitemid 34258354)
7. Laverman P, de Vries IJM, Scharenborg NM, de Boer A, Broekema M, Oyen WJG, Figdor CG, Adema GJ and Boerman OC: Development of In-111-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. Nuclear Med Biol 33: 453-458, 2006.
8. Schaft N, Dorrie J, Thumann P, Beck VE, Müller I, Schultz ES, Kampgen E, Dieckmann D and Schuler G: Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 174: 3087-3097, 2005.
9. Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EHJG, Scharenborg NM, de Boer A, van de Rakt MWMM, Kerkhoff M, Gerritsen MJP, Eijkeler F, Bonenkamp JJ, Blokx W, van Krieken JH, Boerman OC, Oyen WJG, Punt CJA, Figdor CG, Adema GJ and de Vries IJM: In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 69: 2927-2934, 2009.
10. Schuurhuis DH, Lesterhuis WJ, Kramer M, Looman MGM, Hout-Kuijer M, Schreibelt G, Boullart ACI, Aarntzen EHJG, Benitez-Ribas D, Figdor CG, Punt CJA, de Vries IJM and Adema GJ: Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother 58: 1109-1115, 2009.
11. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H and Gaudernack G: Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13: 905-918, 2006.
12. Kyte JA, Kvalheim G, Lislerud K, Straten PT, Dueland S, Aamdal S and Gaudernack G: T-Cell responses in melanoma patients after vaccination with tumor-mRNA-transfected dendritic cells. Cancer Immunol Immunother 56: 659-675, 2007. (Pubitemid 46348735)
13. Lesterhuis WJ, de Vries IJM, Schuurhuis DH, Boullart ACI, Jacobs JFM, de Boer AJ, Scharenborg NM, Brouwer HMH, van de Rakt MWMM, Figdor CG, Ruers TJ, Adema GJ and Punt CJA: Vaccination of colorectal cancer patients with CEA-Ioaded dendritic cells: antigen-specific T-cell responses in DTH skin tests. Ann Oncol 17: 974-980, 2006.
14. Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E and Schuler G: Efficient elutriation of monocytes within a closed system (Elutra™ ) for clinical-scale generation of dendritic cells. J Immunol Methods 295: 61-72, 2005.
15. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM and Schlom J: Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 57: 982-990, 1995.
16. de Vries IJM, Eggert AAO, Scharenborg NM, Vissers JLM, Lesterhuis WJ, Boerman OC, Punt CJA, Adema GJ and Figdor CG: Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 25: 429-438, 2002.
17. de Vries IJM, Lesterhuis WJ, Scharenborg NM, Engelen LPH, Ruiter DJ, Gerritsen MJP, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG and Punt CJA: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9: 5091-5100, 2003.
18. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G and Thurnher M: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen-pulsed dendritic cells. J Urol 161: 777-782, 1999. (Pubitemid 29422365)
19. de Vries IJM, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJP, Ruiter DJ, Figdor CG, Punt CJA and Adema GJ: Immunomonitoring tumor-specific T-cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23: 5779-5787, 2005.
20. Fong L, Hou YF, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM and Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 95: 8809-8814, 2001.
21. Foon KA, Yannelli J and Bhattacharya-Chatterjee M: Colorectal cancer as a model for immunotherapy. Clin Cancer Res 5: 225-236, 1999.
22. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK and BhattacharyaChatterjee M: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17: 2889-2895, 1999.
23. Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H and Magnusson CGM: Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res 62: 1364-1369, 2002. (Pubitemid 34407793)
24. Zhu MZ, Marshall J, Cole D, Schlom J and Tsang KY: Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 6: 24-33, 2000.
25. Berinstein NL: Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review. J Clin Oncol 20: 2197-2207, 2002.
26. Horig H, Medina FA, Conkright WA and Kaufman HL: Strategies for cancer therapy using carcinoembryonic antigen vaccines. Exp Rev Mol Med 2: 1-24, 2000.
27. Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TNM, Haanen JB, Burg SHD, Melief CJM and Offringa R: Balancing between antitumor efficacy and autoimmune pathology in T-cell mediated targeting of carcinoembryonic antigen. Cancer Res 65: 8446-8455, 2008.
28. Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Günther H, Kohne CH, Ehninger G, Schmitz M and Bornhauser M: Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 55: 268-276, 2006.
29. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, Ideno N, Takesako K, Mitsuhashi M, Orita K and Yamagishi H: Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 51: 99-106, 2002.
30. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B and Fong L: Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class 1 peptides. J Immunother 30: 762-772, 2007.
31. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH and Whang-Peng J: Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 10: 2645-2651, 2004.
32. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK and Gilboa E: Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16: 364-369, 1998.
33. Strimpakos AS, Cunningham D, Mikropoulos C, Petkar I, Barbachano Y and Chau I: The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol 21: 1013-1019, 2010.